Advertisement

Famlliäre adenomatöse Polyposis

  • Waltraut Friedl
  • Christof Lamberti
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Die farniliäre adenomatöse Polyposis (FAP; OM1M *175100) ist eine autosomal-dominant erbliche Disposition zu multiplen, oft bis zu mehr eren tausend kolorektalen Adenomen sowie zu verschiedenen extrakolonischen Manifestat ionen. FAP-Patienten haben das bislang größte Risiko, an einem kolorekta len Karzinom zu erkranken. Die regelmafsigen Vorsorgeunt ersuchungen und die Weiterentwicklung der chirurgischen Techniken emöglichen heute bei dieser Patientengruppe eine effiziente Karzinomprophylaxe.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baia S, Kraus C, Wijnen J, Meera Khan P, Ballhausen WG (1996) Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene. Hum Genet 98:528–533Google Scholar
  2. Behrens J, Kries JP von, Kuhl M et al. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638–642PubMedGoogle Scholar
  3. Behrens J, Jerchow B-A, Würtele M et al. (1998) Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β?. Science 280:596–599PubMedGoogle Scholar
  4. Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Möhr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3:121–125PubMedGoogle Scholar
  5. Bodmer WF, Bailey CJ, Bodmer J et al. (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328:614–616PubMedGoogle Scholar
  6. Boolbol SK, Dannenberg AJ, Chadburn A et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556–2560PubMedGoogle Scholar
  7. Brett MCA, Hershman MJ, Glazer G (1994) Other manifestations of familial adenomatous polyposis. In: Phillips RKS, Spigelman AD, Thomson JPS (eds) Familial adenomatous polyposis and other polyposis syndromes. Edward Arnold, London Boston, pp 143–158Google Scholar
  8. Bülow S (1986) Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. Dis Colon Rectum 29:102–107PubMedGoogle Scholar
  9. Bülow S (1987) Familial polyposis coli. Dan Med Bull 34:1–15PubMedGoogle Scholar
  10. Bülow S (1989) Famüial adenomatous polyposis. Ann Med 21:299–307PubMedGoogle Scholar
  11. Bülow S, Sondergaard JO, Witt IN, Larsen E, Tetens G (1984) Mandibular osteomas in familial polyposis coli. Dis Colon Rectum 27:105–108PubMedGoogle Scholar
  12. Bundesärztekammer (1998) Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen. Dtsch Arztebl 56:B1120–1127Google Scholar
  13. Bussey HJR (1975) Familial polyposis coli. Family studies, histopathology, differential diagnosis and results of treatment. Johns Hopkins University Press, BaltimoreGoogle Scholar
  14. Caspari R, Friedl W, Boker T et al. (1993) Predictive diagnosis in familial adenomatous polyposis: evaluation of molecular genetic and ophthalmologic methods. Z Gastroenterol 31:646–652PubMedGoogle Scholar
  15. Caspari R, Friedl W, Mandl M et al. (1994) Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet 343:629–632PubMedGoogle Scholar
  16. Caspari R, Olschwang S, Friedl W et al. (1995) Familial adenomatous polyposis: desmoid tumors and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4:337–340PubMedGoogle Scholar
  17. Chiù CH, McEntee MF, Whelan J (1997) Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 57:4267–4273PubMedGoogle Scholar
  18. Church J, McGannon E, Burke C (1999) Development of prophylactic surgery for familial adenomatous polyposis. J Gastroenterol Hepathol 14:A65Google Scholar
  19. Clark SK, Phillips RK (1996) Desmoids in familial adenomatous polyposis. Br J Surg 83:1494–1504PubMedGoogle Scholar
  20. Clark SK, Neale KF, Landgrebe JC, Phillips RK (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86:1185–1189PubMedGoogle Scholar
  21. DeCosse JJ, Miller HH, Lesser ML (1989) Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 81:1290–1297PubMedGoogle Scholar
  22. De Rosa M, Scarano MI, Panariello L et al. (1999) Three submicroscopic deletions at the APC locus and their rapid detection by quantitative-PCR analysis. Eur J Hum Genet 7:695–703PubMedGoogle Scholar
  23. Dietrich WF, Lander ES, Smith JS et al. (1993) Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75:631–639PubMedGoogle Scholar
  24. Dobbie Z, Heinimann K, Bishop DT, Muller H, Scott RJ (1997) Identification of a modifier gene locus on chromosome lp35-36 in familial adenomatous polyposis. Hum Genet 99:653–657PubMedGoogle Scholar
  25. Eccles DM, Van der Luijt R, Breukel C et al. (1996) Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet 59:1193–1201PubMedGoogle Scholar
  26. Fodde R, Edelmann W, Yang K et al. (1994) A targeted chain-termination mutation in the mouse APC gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 91:8969–8973PubMedGoogle Scholar
  27. Fodde R, Smits R, Hofland N, Kielman M, Meera Khan P (1999) Mechanisms of APC-driven tumorigenesis: lessons from mouse models. Cytogenet Cell Genet 86:105–111PubMedGoogle Scholar
  28. Friedl W, Jungck M (1998) Familiäre adenomatöse Polyposis: Molekulargenetische Diagnostik und klinische Aspekte. Med Genet 10:266–270Google Scholar
  29. Friedl W, Caspari R, Piechaczek B, Propping P (1991) Reliability of presymptomatic test for adenomatous polyposis coli. Lancet 337:1172Google Scholar
  30. Friedl W, Caspari R, Propping P (1994) Diagnostik bei familiärer adenomatöser Polyposis. Dtsch Med Wochenschr 119:27–30PubMedGoogle Scholar
  31. Friedl W, Caspari R, Sengteller M et al. (2001) Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut (im Druck)Google Scholar
  32. Friedl W, Meuschel S, Caspari R et al. (1996) Attenuated familial adenomatous polyposis due to a mutation in the 3′ part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet 97:579–584PubMedGoogle Scholar
  33. Frischmeyer PA, Dietz HC (1999) Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 8:1893–900PubMedGoogle Scholar
  34. Gardner EJ, Richards RC (1953) Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 5:139–148PubMedGoogle Scholar
  35. Gebert JF, Dupon C, Kadmon M et al. (1999) Combined molecular and clinical approaches for the identification of families with familial adenomatous polyposis coli. Ann Surg 229:350–361PubMedGoogle Scholar
  36. Giardiello FM (1994) Sulindac and polyp regression. Cancer Metastasis Rev 13:279–83PubMedGoogle Scholar
  37. Giardiello FM, Hamilton SR, Krush AJ et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedGoogle Scholar
  38. Giardiello FM, Brensinger JD, Petersen GM et al. (1997) The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 336:823–827PubMedGoogle Scholar
  39. Griffioen G, Bus PJ, Vasen HF, Verspaget HW, Lamers CB (1998) Extracolonic manifestations of familial adenomatous polyposis: desmoid tumours, and upper gastrointestinal adenomas and carcinomas. Scand J Gastroenterol Suppl 225:85–91PubMedGoogle Scholar
  40. Groden J, Thliveris A, Samowitz W et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589–600PubMedGoogle Scholar
  41. Hamilton SR, Liu B, Parsons RE et al. (1995) The molecular basis of Turcot’s syndrome. N Engl J Med 332:839–847PubMedGoogle Scholar
  42. Hargest R, Eldin A, Williamson R (1998) Gene therapy for familial adenomatous polyposis. Prolonged expression of the adenomatous polyposis coli gene after lipofection into mouse colon in vivo. Adv Exp Med Biol 451:385–391PubMedGoogle Scholar
  43. He TC, Sparks AB, Rago C et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512PubMedGoogle Scholar
  44. Heiskanen I, Jarvinen HJ (1997) Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Int J Colorectal Dis 12:9–13PubMedGoogle Scholar
  45. Heiskanen I, Kellokumpu I, Jarvinen H (1999) Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 31:412–416PubMedGoogle Scholar
  46. Herfarth C, Kadmon M (1999) Chirurgische Behandlungskonzepte bei hereditären kolorektalen Karzinomen. In: Bundesärztekmmer (Hrsg) Fortschritte und Fortbildung in der Medizin, Bd 23. Deutscher Ärzteverlag, Köln, S 71–77Google Scholar
  47. Herfarth C, Stern J (1990) Colitis ulcerosa — Adenomatosis coli. Funktionserhaltende Therapie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  48. Herrera L (1990) Familial adenomatous polyposis. Liss, New YorkGoogle Scholar
  49. Herrera L, Kakati S, Gibas L, Pietrzak E, Sandberg AA (1986) Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 25:473–476PubMedGoogle Scholar
  50. Hioki K, Shivapurkar N, Oshima H, Alabaster O, Oshima M, Taketo MM (1997) Suppression of intestinal polyp development by low-fat and high-fiber diet in APC(delta716) knockout mice. Carcinogenesis 18:1863–1865PubMedGoogle Scholar
  51. Hodgson SV, Coonar AS, Hanson PJ et al. (1993) Two cases of 5q deletions in patients with familial adenomatous polyposis: possible link with Caroli’s disease. J Med Genet 30:369–375PubMedGoogle Scholar
  52. Jacoby RF, Marshall DJ, Newton MA et al. (1996) Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710–714PubMedGoogle Scholar
  53. Jagelman DG (1990) Evaluation of the gastrointestinal tract in patients with familial adenomatous polyposis. In: Herrera L (ed) Familial adenomatous polyposis. Liss, New York, S 97–100Google Scholar
  54. Joslyn G, Richardson DS, White R, Alber T (1993) Dimer formation by an N-terminal coiled coil in the APC protein. Proc Natl Acad Sci USA 90:11.109–11.113Google Scholar
  55. Kadmon M, Moslein G, Buhr HJ, Herfarth C (1995) [Desmoid tumors in patients with familial adenomatous polyposis (FAP). Clinical and therapeutic observations from the Heidelberg polyposis register], Chirurg 66:997–1005PubMedGoogle Scholar
  56. Kasner L, Traboulsi EI, Delacruz Z, Green WR (1992) A histopathologic study of the pigmented fundus lesions in familial adenomatous polyposis. Retina 12:35–42PubMedGoogle Scholar
  57. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170PubMedGoogle Scholar
  58. Kinzler KW, Nilbert MC, Su LK et al. (1991) Identification of FAP locus genes from chromosome 5q21. Science 253:661–665PubMedGoogle Scholar
  59. Klein WA, Miller HH, Anderson M, DeCosse JJ (1987) The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863–2868PubMedGoogle Scholar
  60. Kommission für Öffentlichkeitsarbeit und ethische Fragen der Gesellschaft für Humangenetik e. V. (1995) Stellungnahme zur genetischen Diagnostik bei Kindern und Jugendlichen. Med Genet 7:358–359Google Scholar
  61. Kurzik-Dumke U, Gundacker D, Renthrop M, Gateff E (1995) Tumor suppression in Drosophila is causally related to the function of the lethal(2) tumorous imaginai discs gene, a DNAJ homolog. Dev Genet 16:64–76PubMedGoogle Scholar
  62. Labayle D, Fischer D, Vielh P et al. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639PubMedGoogle Scholar
  63. Labayle D, Boyer J, Drouhin F, Zarka Y, Fischer D (1994) Sulindac in familial adenomatous polyposis. Lancet 343:417–418PubMedGoogle Scholar
  64. Laken SJ, Petersen GM, Gruber SB et al. (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17:79–83, 1061–4036PubMedGoogle Scholar
  65. Lamlum H, Ilyas M, Rowan A et al. (1999) The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson’s ‚two-hit ‘hypothesis. Nat Med 5:1071–1075PubMedGoogle Scholar
  66. Leppert M, Dobbs M, Scambler P et al. (1987) The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 238:1411–1413PubMedGoogle Scholar
  67. Leppert M, Burt R, Hughes JP et al. (1990) Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. N Engl J Med 322:904–908PubMedGoogle Scholar
  68. Lockhart-Mummery P (1925) Cancer and heredity. Lancet 1:427–429Google Scholar
  69. Lotfi AM, Dozois RR, Gordon H et al. (1989) Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int J Colorectal Dis 4:30–36PubMedGoogle Scholar
  70. Lynch HT, Smyrk TC, Watson P et al. (1992) Hereditary flat adenoma syndrome: a variant of familial adenomatous polyposis? Dis Colon Rectum 35:411–421PubMedGoogle Scholar
  71. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM (1995) The secretory phospholipase A2 gene is a candidate for the Moml locus, a major modifier of APCMin-induced intestinal neoplasia. Cell 81:957–966PubMedGoogle Scholar
  72. Mahmoud NN, Boolbol SK, Dannenberg AJ et al. (1998 a) The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19:87–91PubMedGoogle Scholar
  73. Mahmoud NN, Dannenberg AJ, Mestre J et al. (1998 b) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 124:225–231PubMedGoogle Scholar
  74. Mandl M, Paffenholz R, Friedl W, Caspari R, Sengteller M, Propping P (1994) Frequency of common and novel inactivating APC mutations in 202 families with familial adenomatous polyposis. Hum Mol Genet 3:181–184PubMedGoogle Scholar
  75. Mandl M, Caspari R, Jauch A et al. (1996) Familial adenomatous polyposis: a submicroscopic deletion at the APC locus in a family with mentally normal patients. Hum Genet 97:204–208PubMedGoogle Scholar
  76. Matsumine A, Ogai A, Senda T et al. (1996) Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 272:1020–1023PubMedGoogle Scholar
  77. Miyaki M, Konishi M, Kikuchi Yanoshita R et al. (1994) Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 54:3011–3020PubMedGoogle Scholar
  78. Miyoshi Y, Ando H, Nagase H et al. (1992 a) Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 89:4452–4456PubMedGoogle Scholar
  79. Miyoshi Y, Nagase H, Ando H et al. (1992 b) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1:229–233PubMedGoogle Scholar
  80. Morin PJ (1999) beta-catenin signaling and cancer. Bioessays 21:1021–1030PubMedGoogle Scholar
  81. Morin PJ, Sparks AB, Korinek V et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790PubMedGoogle Scholar
  82. Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322–324PubMedGoogle Scholar
  83. Moser AR, Dove WF, Roth KA, Gordon JI (1992) The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 116:1517–1526PubMedGoogle Scholar
  84. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF (1995) APCMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 31a:1061–1064PubMedGoogle Scholar
  85. Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B, Polakis P (1994) The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res 54:3676–3681PubMedGoogle Scholar
  86. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 92:3046–3050PubMedGoogle Scholar
  87. Nagase H, Miyoshi Y, Horii A et al. (1992 a) Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 52:4055–4057PubMedGoogle Scholar
  88. Nagase H, Miyoshi Y, Horii A et al. (1992 b) Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients. Hum Mutat 1:467–473PubMedGoogle Scholar
  89. Nakatsugi S, Fukutake M, Takahashi M et al. (1997) Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 88:1117–1120PubMedGoogle Scholar
  90. Niv Y, Fraser GM (1994) Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 107:854–857PubMedGoogle Scholar
  91. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618–1619PubMedGoogle Scholar
  92. Offerhaus GJ, Giardiello FM, Krush AJ et al. (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980–1982PubMedGoogle Scholar
  93. Olschwang S, Tiret A, Laurent Puig P, Muleris M, Parc R, Thomas G (1993) Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell 75:959–968PubMedGoogle Scholar
  94. Olschwang S, Laurent Puig P, Melot T, Thuille B, Thomas G (1995) High resolution genetic map of the adenomatous polyposis coli gene (APC) region. Am J Med Genet 56:413–419PubMedGoogle Scholar
  95. Oshima M, Takahashi M, Oshima H et al. (1995) Effects of docosahexaenoic acid (DHA) on intestinal polyp development in APC delta 716 knockout mice. Carcinogenesis 16:2605–2607PubMedGoogle Scholar
  96. Oshima M, Dinchuk JE, Kargman SL et al. (1996) Suppression of intestinal polyposis in APC delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedGoogle Scholar
  97. Paulsen JE, Steffensen IL, Andreassen A, Vikse R, Alexander J (1999) Neonatal exposure to the food mutagen 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. Carcinogenesis 20:1277–1282PubMedGoogle Scholar
  98. Pierre F, Perrin P, Champ M, Bornet F, Meflah K, Menanteau J (1997) Short-chain fructo-oligosaccharides reduce the occurrence of colon tumors and develop gut-associated lymphoid tissue in Min mice. Cancer Res 57:225–228PubMedGoogle Scholar
  99. Polakis P (1997) The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1332:F127–F147PubMedGoogle Scholar
  100. Polkinghorne PJ, Ritchie S, Neale K, Schoeppner G, Thomson JP, Jay BS (1990) Pigmented lesions of the retinal pigment epithelium and familial adenomatous polyposis. Eye 4:216–221PubMedGoogle Scholar
  101. Powell SM, Petersen GM, Krush AJ et al. (1993) Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 329:1982–1987PubMedGoogle Scholar
  102. Quesada CF, Rimata H, Mori M, Nishimura M, Tsuneyoshi T, Baba S (1998) Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice. Jpn J Cancer Res 89:392–396PubMedGoogle Scholar
  103. Ritland SR, Leighton JA, Hirsch RE, Morrow JD, Weaver AL, Gendler SJ (1999) Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the APC(Min) mouse. Clin Cancer Res 5:855–863PubMedGoogle Scholar
  104. Romania A, Zakov ZN, McGannon E, Schroeder T, Heyen F, Jagelman DG (1989) Congenital hypertrophy of the ret-v inai pigment epithelium in familial adenomatous polyposis. Ophthalmology 96:879–884PubMedGoogle Scholar
  105. Rubinfeld B, Souza B, Albert I et al. (1993) Association of the APC gene product with beta-catenin. Science 262:1731–1734PubMedGoogle Scholar
  106. Scott RJ, Van der Luijt R, Spycher M et al. (1995) Novel germline APC gene mutation in a large familial adenomatous polyposis kindred displaying variable phenotypes. Gut 36:731–736PubMedGoogle Scholar
  107. Scott RJ, Froggatt NJ, Trembath RC, Evans DG, Hodgson SV, Maher ER (1996) Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3′ APC gene mutation. Hum Mol Genet 5:1921–1924PubMedGoogle Scholar
  108. Scott RJ, Taeschner W, Heinimann K et al. (1997) Association of extracolonic manifestations of familial adenomatous polyposis with acetylation phenotype in a large FAP kindred. Eur J Hum Genet 5:43–49PubMedGoogle Scholar
  109. Shoemaker AR, Moser AR, Dove WF (1995) N-ethyl-AT-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 55:4479–4485PubMedGoogle Scholar
  110. Smith WG (1958) Multiple polyposis, Gardner’s syndrome and desmoid tumour. Dis Colon Rectum 1:323–332PubMedGoogle Scholar
  111. Smith KJ, Johnson KA, Bryan TM et al. (1993) The APC gene product in normal and tumor cells. Proc Natl Acad Sci USA 90:2846–2850PubMedGoogle Scholar
  112. Smith KJ, Levy DB, Maupin P, Pollard TD, Vogelstein B, Kinzler KW (1994) Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Res 54:3672–3675PubMedGoogle Scholar
  113. Spigelman AD, Thomson JPS (1994) Introduction, history and registries. In: Phillips RKS, Spigelman AD, Thomson JPS (eds) Familial adenomatous polyposis and other polyposis syndromes. Edward Arnold, London Boston, pp 3–14Google Scholar
  114. Spigelman AD, Owen RW, Hill MJ, Phillips RK (1991) Biliary bile acid profiles in familial adenomatous polyposis. Br J Surg 78:321–325PubMedGoogle Scholar
  115. Spirio L, Nelson L, Ward K, Burt R, White R, Leppert M (1993 a) A CA-repeat polymorphism close to the adenomatous polyposis coli (APC) gene offers improved diagnostic testing for familial APC. Am J Hum Genet 52:286–296PubMedGoogle Scholar
  116. Spirio L, Olschwang S, Groden J et al. (1993 b) Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75:951–957PubMedGoogle Scholar
  117. Spirio LN, Kutchera W, Winstead MV et al. (1996) Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli. Cancer Res 56:955–958PubMedGoogle Scholar
  118. Spirio LN, Samowitz W, Robertson M, Burt RW, Leppert M, White R (1998) Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 20:385–388PubMedGoogle Scholar
  119. Steffensen IL, Paulsen JE, Eide TJ, Alexander J (1997) 2-Amino-1-methyl-6-phenylimidazo[4,5-b] pyridine in-creases the numbers of tumors, cystic crypts and aberrant crypt foci in multiple intestinal neoplasia mice. Carcinogenesis 18:1049–1054PubMedGoogle Scholar
  120. Su LK, Johnson KA, Smith KJ, Hill DE, Vogelstein B, Kinzler KW (1993) Association between wild type and mutant APC gene products. Cancer Res 53:2728–2731PubMedGoogle Scholar
  121. Su LK, Burrell M, Hill DE et al. (1995) APC binds to the novel protein EB1. Cancer Res 55:2972–2977PubMedGoogle Scholar
  122. Talbot IC (1994) Pathology. In: Phillips RKS, Spigelman AD, Thomson JPS (eds) Familial adenomatous polyposis and other polyposis syndromes. Edward Arnold, London Boston, pp 15–35Google Scholar
  123. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin Dl in colon carcinoma cells. Nature 398:422–426PubMedGoogle Scholar
  124. Thliveris A, Albertsen H, Tuohy T et al. (1996) Long-range physical map and deletion characterization of the 1100-kb Noti restriction fragment harboring the APC gene. Genomics 34:268–270PubMedGoogle Scholar
  125. Thomas HJ, Whitelaw SC, Cottrell SE et al. (1996) Genetic mapping of hereditary mixed polyposis syndrome to chromosome 6q. Am J Hum Genet 58:770–776PubMedGoogle Scholar
  126. Tonelli F, Valanzano R, Dolara P (1994) Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Dig Dis Sci 12:259–264Google Scholar
  127. Traboulsi EI, Krush AJ, Gardner EJ et al. (1987) Prevalence and importance of pigmented ocular fundus lesions in Gardner’s syndrome. N Engl J Med 316:661–667PubMedGoogle Scholar
  128. Traboulsi EI, Murphy SF, Cruz ZC de la, Maumenee IH, Green WR (1990) A clinicopathologic study of the eyes in familial adenomatous polyposis with extracolonic manifestations (Gardner’s syndrome). Am J Ophthalmol 110:550–561PubMedGoogle Scholar
  129. Turcot J, Després J-P, Pierre F (1959) Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 2:465–468PubMedGoogle Scholar
  130. Utsunomiya J, Nakamura T (1975) The occult osteomatous changes in the mandible in patients with familial polyposis coli. Br J Surg 62:45–51PubMedGoogle Scholar
  131. Van der Luijt R, Khan PM, Vasen H et al. (1994) Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics 20:1–4PubMedGoogle Scholar
  132. Van der Luijt RB, Khan PM, Vasen HF et al. (1997) Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. Hum Mutat 9:7–16PubMedGoogle Scholar
  133. Vasen HF, Van der Luijt RB, Slors JF et al. (1996) Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 348:433–435PubMedGoogle Scholar
  134. Vasen HFA, Bülow S, Group aTLCP (1999) Guidelines for the surveillance and management of familial adenomatous polyposis (FAP): a world wide survey among 41 registries. Colorectal Dis 1:214–221Google Scholar
  135. Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedGoogle Scholar
  136. Wallis YL, Macdonald F, Hulten M et al. (1994) Genotypephenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 94:543–548PubMedGoogle Scholar
  137. Wallis YL, Morton DG, McKeown CM, Macdonald F (1999) Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36:14–20PubMedGoogle Scholar
  138. Wechter WJ, Kantoci D, Murray ED et al. (1997) R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 57:4316–4324PubMedGoogle Scholar
  139. Williams CS, Luongo C, Radhika A et al. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111:1134–1140PubMedGoogle Scholar
  140. Williamson SL, Kartheuser A, Coaker J et al. (1999) Intestinal tumorigenesis in the APC1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 20:805–810PubMedGoogle Scholar
  141. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H (1993) The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 8:13–17PubMedGoogle Scholar
  142. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H (1995) Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 38:813–830PubMedGoogle Scholar
  143. Yang K, Edelmann W, Fan K et al. (1998) Dietary modulation of carcinoma development in a mouse model for human familial adenomatous polyposis. Cancer Res 58:5713–5717PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Waltraut Friedl
    • 1
  • Christof Lamberti
    • 2
  1. 1.Institut für HumangenetikRheinische Friedrich-Wilhelms-Universität BonnBonn
  2. 2.Medizinische Klinik IRheinische Friedrich-Wilhelms-Universität BonnBonn

Personalised recommendations